Default company panoramic image


Xpress is a biotechnology platform for companies needing therapeutic and diagnostic biomolecules for pre-clinical assays.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Liege, Walloon Region, Belgium
  • Currency EUR
  • Founded December 2013
  • Employees 5

Company Summary

Xpress is a biotechnology platform, acting as a service provider, for companies needing therapeutic and diagnostic biomolecules for pre-clinical assays. Xpress will target the human/veterinary therapeutic and vaccine markets. It will mainly be focused on european small/medium biotechs, academic labs, public health organization. It will fill the gap between small requirements during R&D phases and large production required during clinical phases.


  • Default avatar
    Philippe Ledent
    Operations Manager

    Philippe Ledent, PhD in Biochemistry in 1995, acquired extensive experience in molecular biology, fermentation, protein purification & characterization. He held different positions as Scientist, Project Leader, R&D Manager and currently as Manager of a Process Transfer & Development department. He is author of multiple publications and patents in the environmental biotechnology and biologics manufacturing domains.

  • Default avatar
    Christian Rodriguez
    Scientific Manager

    Christian Rodriguez, PhD in Biochemistry in 2005. He developed fermentation/purification processes first at an academic level and then as R&D Manager in a spin-off company. He is currently Project Leader for a Process Transfer & Development department where he is in charge of the scientific strategy and development of projects related to biopharmeuticals. He is author of multiple publications and has recently been awarded by an Innovation Prize.

  • Default avatar
    Marc Daukandt
    Sales and Marketing Manager

    Marc Daukandt, graduated in 1994 with an MSc in Biochemistry, worked 6 years at the University of Liège where he accumulated extensive experience in molecular biology. He then supervised sequencing platforms for 2 different private companies. He also managed a DNA array production lab and is since 2008, in charge of the New Technologies Development Department whose mission is to develop new technologies for the production of biomolecules.


  • Default avatar
    John Troisfontaines (European Fiduciary of Luxembourg Sarl)